Chronomics provides a test that combines Epigenome Sequencing with Machine Learning. The company provides actionable epigenetic insights. Chronomics is focused on health, wellbeing and prevention of age and lifestyle related diseases by monitoring and reducing risk factors.
While DNA sequence is fixed from birth, environmental factors and lifestyle can trigger epigenetic changes. Chronomics analyses the epigenetic mark called DNA methylation which is a methyl group added to DNA. DNA methylation mostly occurs on cytosine bases where cytosine is followed by a guanine base (CpG site). There are more than 28 million CpG sites in the human genome and the methylation readout is a binary variable. Each site is methylated or not methylated and the methylation state is influenced by genetics, the environment and health.
Chronomics uses saliva, which contains buccal epithelial cells and leukocytes, for DNA methylation profiling. Saliva DNA methylation profiles are correlated with those in blood and brain, so saliva can be used to capture effects associated with many complex traits. Users are also asked to fill out a lifestyle questionnaire. To interpret their results, users share their data with Chronomics' team of healthcare professionals, to help provide personalised recommendations to become healthier. Users can test annually to look for health improvements over time.
As of November 2019, Chronomics is serving private healthcare, practitioners and preventive healthcare programs in major health systems, and has stated that they plan to enter into pharmaceutical, biotechnology, and insurance.
Chronomics secured £1.12million in seed funding. The Cambridge start-up got the backing of venture investment firm Anthemis and follow-on funding from early-stage biotech investor SOSV.
Head of Growth
Dr Daniel Herranz
Dr Tom Stubbs
Head of Operations
Chronomics secures seed funding, policymakers urged to put tech talent "at the top of the agenda", and more EU news in brief
January 16, 2019
cuRRBS: simple and robust evaluation of enzyme combinations for reduced representation approaches. - PubMed - NCBI
pubmeddev, Martin-Herranz DE , et al.
DNA test predicts everything from longevity to whether you'll get heart disease or cancer
By Jonathan Gornall For The Daily Mail
July 15, 2019
Epigenetic testing firms claim to help you live a healthier lifestyle
Meet the Startup: Chronomics' epigenetics out of the lab - Longevity.Technology
November 12, 2019
Multi-tissue DNA methylation age predictor in mouse. - PubMed - NCBI
pubmeddev, Stubbs TM , et al.
Reset Your DNA to Slow the Clock
October 25, 2018
Screening for genes that accelerate the epigenetic aging clock in humans reveals a role for the H3K36 methyltransferase NSD1
Daniel E. Martin-Herranz, Erfan Aref-Eshghi, Marc Jan Bonder, Thomas M. Stubbs, Sanaa Choufani, Rosanna Weksberg, Oliver Stegle, Bekim Sadikovic, Wolf Reik, Janet M. Thornton
August 14, 2019
We Are More Than Our DNA
November 17, 2018
Documentaries, videos and podcasts
Ageing Environments and Epigenetics: Dr. Tom Stubbs, CEO of Chronomics
November 18 2018
AXA Health Tech & You Awards | Chronomics
July 2nd 2019
CEO Tom Stubbs Makes You Understand Epigenetics
July 11, 2019
Chronomics pitching on the main stage at Web Summit 2019
November 6th 2019
Dr. Daniel Herranz interviewed at the Biohacker's Summit 2019
November 2nd 2019
Epigenetics With Dr. Tom Stubbs (Biohacker's Live show)
June 24 2019
Frontier Epigenetics with Dr. Tom Stubbs | Decoding Superhuman
January 3rd 2019
- SOSVSOSV (formerly SOS Ventures) is a venture capital firm founded in 1995 by Sean O'Sullivan that provides growth, seed, and venture capital funding to startups. SOSV runs six seed accelerator programs: HAX Accelerator, Chinaccelerator, MOX, IndieBio, RebelBio, and Food-X.
- RebelBioRebelBio is a startup accelerator backed by SOSV supporting companies creating products and services based on life science technologies.